

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM836358

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Technical Prospects, LLC		08/31/2023	Limited Liability Company: WISCONSIN
RECEIVING PARTY DATA			
Name:	Apogem Capital LLC, as Agent		
Street Address:	227 West Monroe Street, Suite 5400		
City:	Chicago		
State/Country:	ILLINOIS		
Postal Code:	60606		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	5375189	LET'S GET TECHNICAL	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	sharon.elkin@katten.com		
Correspondent Name:	Sharon Elkin c/o Katten Muchin Rosenman		
Address Line 1:	525 W. Monroe Street		
Address Line 4:	Chicago, ILLINOIS 60661		
ATTORNEY DOCKET NUMBER:	214338-00622		
NAME OF SUBMITTER:	Sharon Elkin		
SIGNATURE:	/Sharon Elkin/		
DATE SIGNED:	09/01/2023		
Total Attachments: 5			
source=apogem directmed trademark security agreement final 2023 (Technical Prospects) executed#page1.tif			
source=apogem directmed trademark security agreement final 2023 (Technical Prospects) executed#page2.tif			
source=apogem directmed trademark security agreement final 2023 (Technical Prospects) executed#page3.tif			
source=apogem directmed trademark security agreement final 2023 (Technical Prospects) executed#page4.tif			
source=apogem directmed trademark security agreement final 2023 (Technical Prospects) executed#page5.tif			

CH \$40.00 5375189

TRADEMARK SECURITY AGREEMENT

THIS TRADEMARK SECURITY AGREEMENT (this “**Agreement**”) is made as of August 31, 2023, by TECHNICAL PROSPECTS, LLC, a Wisconsin limited liability company (“**Grantor**”), in favor of APOGEM CAPITAL LLC (as successor by appointment to Madison Capital Funding LLC), in its capacity as Agent for the Lenders (as defined in the Credit Agreement referenced below) (in such capacity, “**Grantee**”):

W I T N E S S E T H

WHEREAS, DirectMed Parts & Service Acquisition, LLC, a Delaware limited liability company (“DirectMed Acquisition”), DirectMed Parts & Service, LLC, a Delaware limited liability company (“DirectMed”; DirectMed and DirectMed Acquisition each individually a “Borrower” and collectively as the “Borrowers”), the financial institutions party thereto from time to time, as Lenders, and Grantee have entered into that certain Credit Agreement dated as of June 30, 2021 (as amended, restated, supplemented or otherwise modified from time to time, the “**Credit Agreement**”), pursuant to which Grantee and Lenders have agreed, subject to the terms and conditions thereof, to make certain loans to, and other credit accommodations in favor of, Borrowers (collectively, the “**Loans**”). Capitalized terms used herein but not otherwise defined shall have the meanings ascribed thereto in the Credit Agreement or the Guarantee and Collateral Agreement (as defined below), as applicable.

WHEREAS, pursuant to the terms of that certain Guarantee and Collateral Agreement dated as of June 30, 2021 among Grantee, Grantor and the other Loan Parties (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “**Guarantee and Collateral Agreement**”), Grantor has granted to Grantee, for its benefit and the benefit of Lenders, a security interest and lien upon substantially all assets of Grantor, including all right, title and interest of Grantor in, to and under all now owned and hereafter acquired Trademarks (as defined in the Guarantee and Collateral Agreement including registrations and applications therefor), and all products and proceeds thereof, to secure the payment of all amounts owing by Borrowers under the Credit Agreement.

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantor agrees as follows:

1. Guarantee and Collateral Agreement Controls. If there is a conflict between the Guarantee and Collateral Agreement and this Agreement, the terms of the Guarantee and Collateral Agreement shall control.

2. Grant and Reaffirmation of Grant of Security Interests. To secure the payment and performance of the Obligations, Grantor hereby grants to Grantee, for its benefit and the benefit of Lenders, and hereby reaffirms its prior grant pursuant to the Guarantee and Collateral Agreement of, a continuing security interest in Grantor’s entire right, title and interest in and to the following (all of the following items or types of property being herein collectively referred to as the “**Trademark Collateral**”), whether now owned or existing or hereafter created, acquired or arising:

(a) all of its Trademarks and all Trademark Licenses providing for the grant by or to Grantor of any right under any Trademark, including, without limitation, those referred to on Schedule A hereto;

(b) all renewals and extensions of the foregoing;

(c) all goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

(d) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

Notwithstanding anything to contrary contained in this Section 2, the security interest granted under this Agreement shall not extend to, and the Trademark Collateral shall not include, any United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant of a security interest therein would impair the validity or enforceability of or render void or result in the cancellation of, any registration issued as a result of such intent-to-use trademark applications under applicable Law; provided that upon submission to and acceptance by the USPTO of an amendment to allege use pursuant to 15 U.S.C. Section 1051(c) or a statement of use pursuant to 15 U.S.C. Section 1051(d) (or any successor provision), such intent-to-use trademark application shall be considered Trademark Collateral. The Grantors and the Agent, on behalf of the Lenders, hereby acknowledge and agree that the security interest created hereby in the Trademark Collateral is not to be construed as an assignment of any Trademarks.

3. Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES.

4. Recordation. The Grantor authorizes and requests that the Commissioner of Patents and Trademarks record this Trademark Security Agreement.

5. Counterparts. This Trademark Security Agreement may be executed in any number of counterparts and by different parties hereto on separate counterpart signature pages, each constituting an original, but all together one and the same instrument. Delivery of an executed counterpart of a signature page of this Trademark Security Agreement by telecopier or other electronic transmission (PDF or TIFF format) shall be effective as delivery of a manually executed counterpart of this Trademark Security Agreement.

Remainder of Page Intentionally Left Blank; Signature Page Follows

IN WITNESS WHEREOF, Grantor has duly executed this Agreement as of the date first written above.

TECHNICAL PROSPECTS, LLC

By: 

Name: Bradley W. de Koning


Title: Chief Executive Officer

Trademark Security Agreement

TRADEMARK
REEL: 008185 FRAME: 0613

Agreed and Accepted
As of the Date First Written Above:

APOGEM CAPITAL LLC,
as Agent

By: 
Name: Curtis Krumreich
Title: Director

Schedule A

Trademark Registrations

Trademark	Registration No.	Registration Date	Jurisdiction
LET'S GET TECHNICAL	5375189	1/09/18	U.S.

Trademark Applications

None.

Intellectual Property Licenses

None.